Kymera TherapeuticsListed
kymeratx.combiotech_life_sciences
Kymera is a clinical-stage biotechnology company focused on developing innovative medicines through targeted protein degradation, aiming to address critical health problems and im…
Portfolio
A closer look at the companies associated with this firm. Verified team members can update the portfolio after signing in.
This is the portfolio currently shown on the public firm page.
Kymera is a clinical-stage biotechnology company focused on developing innovative medicines through targeted protein degradation, aiming to address critical health problems and im…
Editas Medicine is a pioneering gene editing company focused on developing transformative medicines using CRISPR technology to treat serious diseases.
Alnylam Pharmaceuticals is a leading company in the field of RNA interference (RNAi) therapeutics, focusing on the development of innovative medicines for genetic diseases.
Exelixis is a multi-platform cancer company innovating with small molecules and biotherapeutics to develop a diversified portfolio of cancer treatments.
Horizonte Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for individuals affected by rar…
MorphoSys is a biotechnology company focused on developing innovative therapies. They have conducted research on MOR202 in combination with low-dose dexamethasone and continue to…
Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases.
Harnessing breakthrough science to advance hematology care, focusing on innovative treatments for hematologic diseases.
A biotechnology company developing nucleic acid therapies for rare diseases.
Q32 Bio is focused on developing innovative therapies for autoimmune and inflammatory diseases, particularly targeting immune system rebalancing.
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductanc…
Akero Therapeutics is focused on developing Efruxifermin (EFX) for the treatment of metabolic diseases, particularly MASH (Metabolic Associated Steatotic Liver Disease).
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new RNA medicines for systemic and renal diseases. With our STRIKE (Selectively Targe…
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Their lead clinical candidate, frevecitinib…
Mariana Oncology, a Novartis company, is pioneering novel radioligand therapies designed to optimize cancer treatment efficacy while minimizing side effects for patients.
nChroma Bio is a genetic medicines company committed to addressing the limitations of existing therapies through a disease-first approach. By combining programmable in vivo delive…
Remix Therapeutics is advancing a new class of therapeutics by modulating RNA processing with small molecules. The company focuses on drug discovery programs that target previousl…
Renasant Bio is pioneering a new approach to treating autosomal dominant polycystic kidney disease (ADPKD) by developing small molecule correctors and potentiators that target the…
Nimbus Therapeutics is focused on developing breakthrough medicines through precision small molecule design, emphasizing selectivity in drug discovery and clinical development.
HotSpot Therapeutics is pioneering a new approach to allosteric drug discovery by unlocking the on/off switches on proteins called 'natural hotspots' to enable differentiated medi…
Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other…
TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel therapeutics to treat diseases. The company focus…
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders. They fo…